Staying Abreast of Best Practices Across the Clinical Continuum

Slides:



Advertisements
Similar presentations
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.
Advertisements

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Overall Goal. Clinical Conversations: Nursing Care for Patients With Multiple Myeloma.
Multimodal Management of Opioid-Induced Constipation
Korde N et al. Proc ASH 2012;Abstract 732.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Highlights: Myeloma Oral Session
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
Perspectives on Triple-Negative Breast Cancer
Improving Survival in Glioblastoma Multiforme
Hot Off the Press: Changes in the Landscape of Multiple Myeloma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background and update from Myeloma XI Dr John Jones
Ask the Onychomycosis Expert, Part 1
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Issues in the Management of Hemophilia: A Best Practice Series
Current and Future Goals in the Treatment of Relapsed CLL
Treating Transplant-Ineligible Patients With Multiple Myeloma
Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Managing IBD in Children
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Tailoring Hemophilia Prophylaxis Therapy
The Nurse View: Best Practices in Multiple Myeloma
Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Pharmacist Perspectives on Novel Agents in Multiple Myeloma
Case Collection in RA: Highlights of an Interactive Workshop
Nontuberculous Mycobacterial Lung Disease
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Advances in Multiple Myeloma
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Hyperhidrosis Is Burdensome!
Gene Therapy: Past, Present, and Future
Optimizing Frontline Care for Older Patients With Multiple Myeloma
Personalized Therapy in Relapsed or Refractory CLL
Treating to Target in MS
When Is Biologic Therapy Appropriate for HS?
How to Select Therapy In Newly Diagnosed CLL
Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.
Approaches in Newly Diagnosed Multiple Myeloma: When and What
Managing Multiple Myeloma in the Elderly
New Classes of Therapy in Multiple Myeloma
Factor Xa Inhibitors in PAD
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Managing Your Patient’s Maintenance Therapy for Multiple Myeloma
EGPA.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Patient Questions and Expert Answers in Psoriasis:
The Role of Maintenance Therapy in Multiple Myeloma
Pregnancy in MS.
On the Cusp: New Approaches for Multiple Myeloma
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
First-Line FCR: Effect of del(17p) on PFS and OS
The Role of Measurable Residual Disease in AML
Renal Function and Myeloma Therapeutics
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
HAE Prophylaxis.
Clinical Challenges in the Patient With Relapsed Multiple Myeloma
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,
Binge Eating Disorder.
Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.
Minimal Residual Disease and Hematologic Malignancies
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Navigating the Journey
Presentation transcript:

Staying Abreast of Best Practices Across the Clinical Continuum

Diagnostic Criteria Multiple Myeloma Requiring Therapy

Newly Diagnosed Multiple Myeloma Primary Induction for SCT Candidates

Newly Diagnosed Multiple Myeloma Maintenance Therapy

Newly Diagnosed Multiple Myeloma Primary Therapy for Nontransplant Candidates

Response Criteria ≥ Complete Response

Response Criteria ≥ Minimal Response

MRD in Multiple Myeloma

MM Agents Approved in 2015

Multiple Myeloma Therapy for Previously Treated Disease

References

References (cont)

References (cont)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)